Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD.

@article{Pascoe2011SafetyTA,
  title={Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD.},
  author={Steve Pascoe and Christine J. Reynolds and Warren W Pleskow and Sheryl Perry and Abdel Hmissi and Guenther Kaiser and Laurence J Brookman},
  journal={International journal of clinical pharmacology and therapeutics},
  year={2011},
  volume={49 2},
  pages={153-61}
}
OBJECTIVES To assess the safety and tolerability of 4 doses of indacaterol, a once-daily beta2-agonist, in subjects with chronic obstructive pulmonary disease (COPD). The 24-h bronchodilator effect and pharmacokinetics of indacaterol were also investigated. METHODS 16 subjects aged 43 - 72 years with mild/moderate COPD were each given single doses of indacaterol of 400, 1,000, 2,000 and 3,000 µg, via a single-dose dry powder inhaler. RESULTS Changes from predose (400, 1,000, 2,000, 3,000 µg… CONTINUE READING